Trihalomethanes (THMs) can form as byproducts during drinking water disinfection, which is crucial for limiting human exposure to disease-causing pathogens. The US Environmental Protection Agency (USEPA), recognizing both the importance of water disinfection for public health protection and potential risks associated with THM exposure, developed disinfection byproduct rules with the parallel goals of ensuring safe drinking water and limiting the levels of THMs in public water systems. The National Health and Nutrition Examination Survey (NHANES) THM blood data can be used as a means for assessing US population exposures to THMs; biomonitoring equivalents (BEs) can provide human health risk-based context to those data. In this paper, we examine the blood THM levels in the 1999-2004 NHANES data to (i) determine weighted population percentiles of blood THMs, (ii) explore whether gender and/or age are associated with blood THM levels, (iii) determine whether temporal trends can be discerned over the 6-year timeframe, and (iv) draw comparisons between population THM blood levels and BEs. A statistically significant decrease in blood chloroform levels was observed across the 1999-2004 time period. Age-related differences in blood chloroform levels were not consistent and no gender-related differences in blood chloroform levels were observed. The concentrations of all four THMs in the blood of US residents from the 2003 to 2004 NHANES dataset are below BEs consistent with the current US EPA reference doses. For bromodichloromethane and dibromochloromethane, the measured median blood concentrations in the United States are within the BEs for the 10 À6 and 10 À4 cancer risk range, whereas measured values for bromoform generally fall below the 10 À6 cancer risk range. These assessments indicate that general population blood concentrations of THMs are in a range considered to be a low to medium priority for risk assessment follow-up, according to the guidelines for interpretation of biomonitoring data using BEs.
Introduction
Trihalomethanes (THMs, including chloroform, bromodichloromethane, dibromochloromethane, and bromoform) are short-lived chemicals to which there is widespread human exposure. THMs are produced when chlorine-based chemicals are used to disinfect public drinking water; the goal of disinfection is to protect human health by reducing human exposure to disease-causing pathogens. However, toxicological studies have demonstrated the potential for adverse health effects from THM exposure at elevated levels, including toxicity to the liver and kidneys and carcinogenicity under chronic bioassay conditions (USEPA, 2005 (USEPA, , 2006c ). In addition, epidemiological studies have suggested potential associations between exposure to THMs and adverse reproductive outcomes (Bove et al., 2002; Windham et al., 2003; Tardiff et al., 2006) . Thus, the US Environmental Protection Agency (USEPA), recognizing both the importance of water disinfection for public health protection and the potential risks associated with THM exposure, developed Disinfection Byproduct Rules (USEPA, 2001 (USEPA, , 2006a with the parallel goals of ensuring safe drinking water and limiting the levels of THMs in public water systems.
The Centers for Disease Control and Prevention (CDC) has released nationally representative data on blood levels of THMs in the United States, collected during three sampling periods (1999-2000, 2001-2002, and 2003-2004) as part of the National Health and Nutrition Examination Survey (NHANES) (CDC, 2003 (CDC, , 2005 . The NHANES data can be used as part of a population-based exposure assessment. However, limited tools are available for linking the biomonitoring exposure data to human health risk.
Various approaches have been used to attempt to interpret the NHANES biomonitoring data in terms of human health. One approach involves deriving correlations between the biomonitoring levels and health effects from epidemiological studies. These efforts have difficulty reconciling the transient and variable nature of the short-lived biomarkers with chronic effects/diseases . Another approach involves estimating the plausible distribution of doses that would yield the resulting distribution of biomonitoring data. The estimated doses can then be compared with established exposure guidance values derived by regulatory agencies, like the reference dose (RfD) established by the USEPA (Tan et al., 2006 (Tan et al., , 2007 . However, this approach is complex, especially for compounds with short half-lives, multiple routes of exposure, and intermittent exposure patterns, and the inherent uncertainties of the reverse dosimetry approach for short-lived compounds have been noted (Sohn et al., 2004; Hays et al., 2007) .
The concept of biomonitoring equivalents (BEs) was introduced to provide a method for conducting a screeninglevel human health risk evaluation of biomonitoring data (Hays et al., 2007) . BEs, developed to serve as an interpretive and risk management tool, are concentrations or ranges of concentrations of a chemical in a biological medium such as blood or urine consistent with existing health-based exposure guidelines like the RfD (Hays et al., 2007 . BEs are screening tools for assessing whether biomonitoring data indicate a large, small, or no margin of safety compared with existing health-based exposure guidelines. In general, BEs are derived from chemical-specific human or animal pharmacokinetic data in a manner that reconstructs the risk assessment's underlying exposure guidance values (e.g. RfDs, reference concentrations) on an internal dose basis. Detailed guidelines for the derivation and communication of BEs are available and BEs have been developed for THMs .
In this paper, we examine the blood THM levels in the 1999-2004 NHANES data to (i) determine weighted population percentiles of blood THMs for each sampling period, (ii) explore whether gender and/or age are associated with blood THM levels, (iii) determine whether temporal trends can be discerned over the 6-year timeframe, and (iv) draw comparisons between population THM blood levels and health-based BEs for individual compounds as well as mixtures.
Methods

Analysis of NHANES Blood Data
THM levels in blood were measured using solid-phase microextraction coupled with gas chromatography and high-resolution mass spectrometry (Bonin et al., 2005 (Harrell et al., 2008; R Development Core Team, 2008) . Confidence intervals for quantiles were calculated using a weighted bootstrap method described by Chamberlain and Imbens (2003) . For examination of percentage non-detects for each of the sampling periods, unweighted data were used. Data on individuals aged 20-59 years were given by CDC, and percentiles for the different age groups within the population were estimated. Temporal trends for the three timeframes were assessed. The hypothesis test used is based on finding the largest value of a such that simultaneous confidence intervals with coverage probability 1-a (based on asymptotic normal approximation to the distribution of the median estimates) for the 3 year's medians fail to overlap. Measurements below the limit of detection (LOD) were assigned a value of the LOD/ ffiffi ffi 2 p . In general, detection limits ranged from 0.2 to 2.4 pg/ml for all three sampling periods. Throughout this paper, the units for blood THMs are pg/ml, or parts per trillion (ppt). A small number of participants within each sampling period had levels of THMs that were above the calibration range (1999-2000: chloroform at 455 and 1570 pg/ml; 2001-2002: chloroform at 623, 693, and 22,000 pg/ml; 2003-2004: bromoform at 310 pg/ml). These values were included in the analyses.
Development of BEs for THMs
Detailed information on the method for deriving BEs for THMs is given in Aylward et al. (2008) . The BE derivation is based on reproducing the existing cancer and non-cancer risk assessments on an internal dose basis to derive estimates of average blood concentrations consistent with external dose benchmarks for cancer (risk-specific doses corresponding to 10 À6 and 10 À4 risk levels) and non-cancer (human-equivalent point of departure and RfD). Each BE is derived through consideration of the toxicological data underlying the respective exposure guidance value, understanding of the pharmacokinetics of THMs in humans, and application of appropriate uncertainty factor components to the toxicological point of departure. The BEs can be used as screening tools to identify whether the measured population concentrations are in the region of low, medium, or high priority for risk assessment follow-up . In accordance with the BE derivation and communication guidelines , biomarker concentrations below the BE RfD (biomarker concentration consistent with the RfD) indicate ''low priority'' for risk assessment follow-up, whereas concentrations in excess of the BE RfD but below the BE POD (biomarker concentration consistent with the human-equivalent point of departure) indicate medium priority, and those in excess of the BE POD indicate high priority for risk assessment followup. For cancer endpoints, the corresponding regions of priority are delineated by the BEs associated with the 10
À6
and 10 À4 risk levels. The BEs for the four THMs based on the currently available exposure guidance values are summarized in Table 1 . If alternative risk assessments based on different underlying toxicological or epidemiological data are conducted, different evaluations of BE values would be required. Details regarding the assumptions and approaches used in their derivation, as well as detailed discussion regarding their limitations and appropriate uses, are presented in Aylward et al. (2008) .
Evaluation of THM Mixtures in Blood
Multiple THMs tend to be formed during water disinfection and likely lead to simultaneous exposure to more than one THM. Therefore, a mixtures risk assessment approach is needed. Regulation of THMs in drinking water is based on a sum of the concentrations of the four compounds; however, the differing toxicological potencies among the four compounds necessitates understanding which compounds contribute to the mixture of THMs in blood. One approach used for mixtures risk assessment in environmental settings for non-cancer endpoints is the hazard index (HI) approach. Briefly, the ratio of the measured dose of each compound in a mixture to the chemical-specific reference value (RfD, for example) is calculated, and these hazard quotients are summed to obtain an HI for the suite of chemicals considered. The current mixtures risk assessment paradigm implies no excess risks when the HI is below 1. Such an approach is most defensible when the chemicals of interest have similar modes of action and target organ toxicities (USEPA, 2007) , and when non-additive interactions among the chemicals of interest are neither known nor suspected. The BEs present an opportunity to attempt a similar approach to the mixtures biomonitoring data available in the NHANES data. Blood concentration estimated based on the relevant internal dose metric in the animal species divided by the appropriate interspecies uncertainty factor (see Aylward et al. (2008) for details on derivation). Interpretation of THM blood levels in the U.S. LaKind et al.
Results
Weighted Population Percentiles of Blood THM Levels for Each Sampling Period and Temporal Trends
Selected weighted population percentiles (pg/ml, 95% CIs) for three NHANES sampling time periods are given in Table 2 . Median levels of chloroform show a statistically significant decline from 1999 -2000 -2004 . Median levels of bromodichloromethane increased across the first two sampling periods, but then declined in 2003-2004 compared with the earliest data. An overall decline in median dibromochloromethane levels was found. Levels of bromoform seem to have first increased and then declined.
Gender and Age Differences for Blood THM Levels within Sampling Periods
Focusing on chloroform (which had the lowest percentage of non-detects of the THMs across all three sampling periods; Table 2 ), there are no consistent trends by age or between men and women across the three sampling periods (Table 3) . The difference in median blood chloroform levels for both men and women decreased considerably between 1999-2000 and 2003-2004 (Table 3) . For 1999-2000, whereas the trend seems to be one of decreasing concentration with increasing age in aggregate, no consistent decrease by age group was found when the sampled population was analyzed by gender (data not shown).
Comparison of Blood THM Levels to BEs
To provide public health perspective on the blood THM levels from the NHANES study, the most current data (the 2003-2004 sampling period) were compared with the BEs developed for each of the four THMs. For chloroform, the BE is based on a value derived for non-cancer effects that is also considered to be protective for cancer (USEPA, 2008 Interpretation of THM blood levels in the U.S. LaKind et al.
indicating low priority for risk assessment follow-up (based solely on comparison to the non-cancer endpoints).
The non-cancer mixture assessment for the four THM compounds using the additive HI approach for each individual resulted in HIs below 1 at the median (0.2) and 95th percentile (0.8) 
Discussion
The availability of nationally representative data on blood THM levels in the United States over multiple years allows for a first look at temporal, gender, and age trends for these chemicals. In addition, with the use of BEs, public health interpretation of these levels can be provided.
A statistically significant decrease in blood chloroform levels was observed across the 1999-2004 time period. This decrease in blood chloroform levels coincides with the implementation of the Stage 1 Disinfectants and Disinfection Byproducts Rule, which required water systems to reduce the annual average of total THM levels to less than 0.08 mg/l (USEPA, 2001) from a previous limit of 0.1 mg/l. Large surface water systems were required to comply with the Stage 1 Disinfectants and Disinfection Byproducts Rule by January 2002 (USEPA, 2001 ). This regulation was implemented to reduce THM exposure and is likely to have contributed to the desired effect. Indeed, we find decreasing blood chloroform between 1999-2000, 2001-2002 and 2003-2004. Although the relationship between the Stage 1 Rule and decreasing levels of blood chloroform levels could be a causal one, decreases in blood chloroform levels could have resulted from differences in a variety of other factors (e.g. changes in non-disinfected private well use, rate of swimming, source water bromide levels) across the three sampling periods.
Consistent declines were not observed for blood levels of the other THMs, but the analyses were impeded by the fact that levels were closer to or below limits of detection. For this reason, we focused on chloroform in our analyses of age-and gender-related trends. Age-related differences in blood chloroform levels were not consistent. For example, median levels generally decreased with increasing age group for the 1999-2000 period, but this was not observed for the 2001-2002 data; there was a small, non-significant difference in levels between youngest and oldest age groups in the 2003-2004 time period. We did not find gender-related differences in blood chloroform levels for any of the time periods.
The derivation of BE values is one effort to provide context and information useful for interpretation of EPA guidance values, general population blood concentrations of THMs are in a range that would be considered to be a low to medium priority for risk assessment follow-up. The statistical evaluation of biomonitoring data from NHANES and the comparison of these data to BEs for the THMs presented here must be considered in the context of the characteristics of THM compounds. THMs are volatile and are rapidly metabolized and eliminated from blood after exposure. Exposures to THMs in water can occur from consumption of water but also after inhalation or dermal exposure during use of water for showering, cooking, dishwashing, and other activities . Such exposures can result in rapid increases in blood concentration followed by rapid declines . Thus, measurement of THM concentrations in blood at any given time does not provide information for an individual regarding either long-term or peak exposure levels. However, the cross-sectional nature of the NHANES study does provide a broad overview of the range of values likely to be encountered in the general US population on a typical ongoing basis.
The BEs used here to provide a screening level evaluation of the NHANES data are based on time-weighted average (not peak) daily blood concentrations consistent with the current RfDs and cancer risk-specific values for the various compounds (changes in those reference values would necessitate reconsideration of the BEs). These BEs and their underlying reference values are based on an assumption of ongoing, lifetime exposures, and interpretation of crosssectional data (whether biomonitoring data or data on concentrations in drinking water) must always be made with this limitation in mind. In comparison, someone experiencing a single, bolus, once per day exposure equivalent to an RfD could experience a peak blood concentration of chloroform approximately five times the 24-h theoretical average blood concentration at that same exposure, which is the concentration reported as the BE. Thus, comparison of the crosssectional data with these BEs based on the lifetime exposure assumption must be made cautiously, given both the inherent within-day variability as well as the potential for variation over longer time frames for these types of data. Comparison of the NHANES data to the BEs provide a rational basis for a screening-level assessment of the public health risks indicated by these data, but results at the upper or lower tails of the NHANES dataset distributions (which may represent transient peak or minimum blood concentrations, respectively) should be interpreted in comparison with the BEs only with a great deal of caution.
The analytical sensitivity achieved in the NHANES 1999-2004 datasets was sufficient to allow detection of the THM compounds in the majority of sampled individuals, and so avoids the limitations of the earlier NHANES III analyses (sampling conducted from 1988 to 1994; Ashley et al., 1994) . However, given the highly transient nature of these compounds, public health interpretation of ongoing exposures would be enhanced by the development of biomarkers of THM exposures that have longer half-lives. Such biomarkers might include urinary metabolites (if stable and selective markers could be discovered) or protein adducts resulting from the reaction of the THM compounds or their metabolites with proteins in blood. Biomarkers that represent more of an integrative measure of exposure would reduce some of the issues with interpreting the tails of the current THM in blood biomarkers.
The NHANES study design is a complex, multistage, probability sample designed to represent the civilian, noninstitutionalized population and, as such, is not designed to necessarily capture individuals who may be occupationally exposed (e.g. people who work in recreational facilities with . Measured National Health and Nutrition Examination Survey (NHANES) blood concentrations (median, 95th percentile) in the context of estimated biomonitoring equivalents (BEs) for bromodichloromethane (BDCM) based on cancer risk-specific doses at levels consistent with the 10 À6 and the 10 À4 risk-specific doses (adapted from Aylward et al., 2008) . The measured blood bromodichloromethane concentrations fall within this range, indicating a ''medium'' priority for risk assessment follow-up in the framework established in the BE guidelines for communication . swimming pools or in water treatment facilities) or special populations such as frequent or competitive swimmers. Thus, conclusions drawn from examination of the NHANES blood concentration data are limited to members of the typical general population and may not apply to these special population groups. Furthermore, studies that attempt to measure potential peak levels of THMs in blood of individuals experiencing temporary and intermittent activities that might be associated with high THM exposures (taking a shower and/or swimming in a chlorinated swimming pool) should not be interpreted using the BE RfD as these BEs are designed to be associated with interpreting steady-state lifetime average blood levels of THMs. Rather, the biomonitoring levels associated with these types of intermittent and temporary elevated exposures may be more appropriate to interpret using a BE associated with an acute exposure guidance value such as the acute duration minimal risk level set by the Agency for Toxic Substances and Disease Registry. Such BEs would likely be several fold higher than the BEs based on lifetime chronic RfD values.
The mixture evaluation presented here is drawn from methods used in risk assessments for situations involving exposure to multiple compounds. In the case of THM compounds, the similarities in non-cancer response endpoints across compounds (liver toxicity) supports, at least in theory, consideration of the mixture using an HI approach, and incorporates an assumption that the exposure levels encountered in the general population are not likely to approach levels in which metabolic interactions and inhibition would occur (Haddad et al., 2006) . We recognize that this approach has not been validated for assessments based on biomonitoring data, but present this analysis as a potential application of an existing risk assessment approach. Other approaches to mixtures can be contemplated, and the BEs may be useful in those approaches as well.
